- Home
- ATAI vs CRVS Comparison
ATAI vs CRVS Comparison
Compare ATAI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- CRVS
- Stock Information
- Founded
- ATAI 2018
- CRVS 2014
- Country
- ATAI Germany
- CRVS United States
- Employees
- ATAI N/A
- CRVS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- CRVS Health Care
- Exchange
- ATAI Nasdaq
- CRVS Nasdaq
- Market Cap
- ATAI 291.5M
- CRVS 257.0M
- IPO Year
- ATAI 2021
- CRVS 2016
- Fundamental
- Price
- ATAI $1.24
- CRVS $3.17
- Analyst Decision
- ATAI Strong Buy
- CRVS Strong Buy
- Analyst Count
- ATAI 4
- CRVS 5
- Target Price
- ATAI $9.00
- CRVS $12.63
- AVG Volume (30 Days)
- ATAI 1.7M
- CRVS 657.7K
- Earning Date
- ATAI 03-17-2025
- CRVS 03-25-2025
- Dividend Yield
- ATAI N/A
- CRVS N/A
- EPS Growth
- ATAI N/A
- CRVS N/A
- EPS
- ATAI N/A
- CRVS N/A
- Revenue
- ATAI $308,000.00
- CRVS N/A
- Revenue This Year
- ATAI N/A
- CRVS N/A
- Revenue Next Year
- ATAI $20.00
- CRVS N/A
- P/E Ratio
- ATAI N/A
- CRVS N/A
- Revenue Growth
- ATAI N/A
- CRVS N/A
- 52 Week Low
- ATAI $1.03
- CRVS $1.30
- 52 Week High
- ATAI $2.85
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ATAI 36.74
- CRVS 27.95
- Support Level
- ATAI $1.42
- CRVS $3.20
- Resistance Level
- ATAI $1.58
- CRVS $3.45
- Average True Range (ATR)
- ATAI 0.12
- CRVS 0.38
- MACD
- ATAI -0.00
- CRVS -0.11
- Stochastic Oscillator
- ATAI 4.55
- CRVS 6.43
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).